Insmed (INSM) reported a third-quarter 2024 loss of $1.27 per share, wider than the Zacks Consensus Estimate of a loss of $1.19. In the year-ago quarter, the company posted a loss of $1.11 per share.Insmed generated total revenues of $93.4 million during the quarter, up 18% year over year. Quarterly sales were in line with the Zacks Consensus Estimate.Shares of INSM were down more than 4% on Thursday likely due to the earnings miss.See the Zacks Earnings Calendar to stay ahead of market-making news.Year to ...

Insmed Incorporated (NASDAQ:INSM) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Bryan Dunn – Head of Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer – Chief Medical Officer Conference Call Participants Joe Schwartz – Leerink Partners Jessica Fye – JPMorgan Nicole Germino – Truist Securities Jason Zemansky – Bank of America Jennifer Kim – Cantor Jeff Hung – Morgan Stanley Leon Wang – Barclays Steve W ...

Insmed (INSM) reported $93.43 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 18.2%. EPS of -$1.27 for the same period compares to -$1.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $93.31 million, representing a surprise of +0.12%. The company delivered an EPS surprise of -6.72%, with the consensus EPS estimate being -$1.19.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Insmed (INSM) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $1.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.72%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.22 per share when it actually produced a loss of $1.94, delivering a ...

Exhibit 99.1 1 Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025— —Expanded U.S. Sales Force is Now Fully Deployed; Focusing on Bronchiectasis Disease-State Awa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 54-1972729 (State or other jurisdi ...

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023——NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025——Expanded U.S. Sales Force is Now Fully Deployed; Focusing on Bronchiectasis Disease-State Awareness and Supporting the Growth of ARIKAYCE Prior to the Anticipated Launch of Brensocatib——Ends ...

Wall Street analysts forecast that Insmed (INSM) will report quarterly loss of $1.19 per share in its upcoming release, pointing to a year-over-year decline of 8.2%. It is anticipated that revenues will amount to $93.31 million, exhibiting an increase of 18% compared to the year-ago quarter. The consensus EPS estimate for the quarter has undergone an upward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their ini ...

Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Oct. 23, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today holds its third annual Global Day of Good, with more than 1,000 employees volunteering simultaneously in their respe ...

BRIDGEWATER, N.J., Oct. 17, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2024 financial results on Thursday, October 31, 2024. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, October 31, 2024, to discuss the financial results and p ...